Merck-Serono believes Cladribine was victim of regulatory stigma
This article was originally published in Scrip
Executive Summary
Merck Serono Europe told the European Medicines Agency formally on 17 February that it had decided to withdraw its application for a centralised marketing authorisation for Movectro (cladribine) in the treatment of relapsing remitting multiple sclerosis.